Humira Buyers Take AbbVie Antitrust Challenge To 7th Circ.

Law360 (July 30, 2020, 6:18 PM EDT) -- Humira buyers are appealing to the Seventh Circuit an Illinois federal judge's dismissal of their proposed class action claiming AbbVie Inc. built a "patent thicket" around the immunosuppressant drug to block cheaper biosimilars from entering the market.

The buyers offered no details of the appeal other than informing U.S. District Judge Manish Shah in a one-sentence notice on Tuesday about their bid to undo his ruling issued last month.

The Humira purchasers launched their novel claims in May 2019, alleging AbbVie's colossal "patent thicket" for its $20-billion-per-year immunosuppressant Humira has empowered it to block less-expensive biosimilars in violation of numerous antitrust laws....

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!